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Abstract: Sifuvirtide, a 36 amino acid negatively charged peptide, is a novel and promising HIV fusion
inhibitor, presently in clinical trials. Because of the aromatic amino acid residues of the peptide, its behavior
in aqueous solution and the interaction with lipid-membrane model systems (large unilammelar vesicles)
were studied by using mainly fluorescence spectroscopy techniques (both steady-state and time-resolved).
No significant aggregation of the peptide was observed with aqueous solution. Various biological and
nonbiological lipid-membrane compositions were analyzed, and atomic force microscopy was used to
visualize phase separation in several of those mixtures. Results showed no significant interaction of the
peptide, neither with zwitterionic fluid lipid membranes (liquid-disordered phase), nor with cholesterol-rich
membranes (liquid-ordered phase). However, significant partitioning was observed with the positively charged
lipid models (Kp ) (2.2 ( 0.3) × 103), serving as a positive control. Fluorescence quenching using Förster
resonance acrylamide and lipophilic probes was carried out to study the location of the peptide in the
membrane models. In the gel-phase DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine) membrane model,
an adsorption of the peptide at the surface of these membranes was observed and confirmed by using
Förster resonance energy-transfer experiments. These results indicate a targeting of the peptide to gel-
phase domains relatively to liquid-disordered or liquid-ordered phase domains. This larger affinity and
selectivity toward the more rigid areas of the membranes, where most of the receptors are found, or to
viral membrane, may help explain the improved clinical efficiency of sifuvirtide, by providing a local increased
concentration of the peptide at the fusion site.
1. Introduction
Human immunodeficiency virus type 1 (HIV-1) envelope
glycoprotein subunits gp120 and gp41 play a crucial role in
the early steps of the viral binding and entry to the target CD4+
host cells.1 After binding of the surface protein gp120 to CD4
and CCR5 (or CXCR4) receptors, a conformational change in
the transmembrane protein gp41 is triggered, resulting in the
exposure and insertion of a fusion peptide in the target cell
membrane. This leads to the interaction of the heptad repeat
domains of gp41 (HR1 and HR2), allowing the fusion of two
membranes (viral and target cell). (See refs 2–4 and references
therein).
Targeting this HR1/HR2 interaction allowed the development
of HIV-1 fusion inhibitors, such as enfuvirtide (FDA-approved
drug) and T-1249 (development currently interrupted)4–7 (Figure
1). Both peptides present high therapeutic potency, but the
natural side effects and mainly the emergence of undesired
resistant strains of the virus are common in a prolonged
administration of any antiretroviral drug. To overcome these
problems, the discovery of more potent and less toxic inhibitors
is a priority. Furthermore, the interfacial physical chemistry on
the lipid surface of cells and enveloped viruses is crucial in the
action of peptides that prevent such viruses from entering the
cells.
Sifuvirtide (Figure 1), a novel HIV fusion inhibitor developed
through structure-based drug design by FusoGen Pharmaceu-
ticals, Inc. (Tianjin, P. R. China),8,9 overcomes several of these
problems, profiling itself as a suitable and promising alternative
to enfuvirtide. This 36 amino acid peptide is actually in phase
II clinical trials in China and presents higher fusion inhibition† Faculdade de Medicina da Universidade de Lisboa.
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activity (20× more activity) and improved stability.8,9 Clinical
trials in the United States are already programmed.
The presence of amphipathic segments, the analysis of the
sequence, and the theoretical R-helical content10,11 and hydro-
phobicity study12 of the amino acid residues suggest that
sifuvirtide may interact with biological membranes. The fact
that sifuvirtide presents tryptophan residues in its sequence
enabled the use of fluorescence spectroscopy techniques13 to
study its behavior in aqueous solution, its interaction with bio
membrane models (large unilammelar vesicles), and its location
in phospholipid bilayers.
Previous studies revealed that the fusion inhibitors enfuvirtide
and T-1249 interact with membranes in a different way.
Enfuvirtide inserts preferentially in fluid-phase lipid mem-
branes,14 whereas T-1249 may also adsorb on the surface of
cholesterol-rich membranes.15 The interaction of these peptides
with biological membranes may be related to their inhibition
efficacy and mode of action, because the binding to gp41 occurs
in an extreme confinement between the cellular membrane and
viral envelope. (See ref 16 and references therein).
The aim of this work is to verify the possible interaction of
sifuvirtide with lipid membranes, compare it with the results
already obtained for enfuvirtide and T-1249, and relate the
structural features of these peptides to their different efficiencies
to inhibit the HIV-1 fusion process.
2. Materials and Methods
2.1. Materials. Sifuvirtide was a kind gift from FusoGen
Pharmaceuticals, Inc. 1-Palmitoyl-2-oleoyl-sn-glycero-3-phospho-
choline (POPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-ethylphospho-
choline (EPOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine
(DPPC), 1,2-dipalmitoyl-sn-glycero-3-[phospho-rac-(1-glycerol)]
(DPPG, Sodium Salt), and N-palmitoyl-D-erythro-sphingosylphos-
phorylcholine (PSM) were purchased from Avanti Polar-Lipids
(Alabaster, AL). 5-Doxylstearic acid (5NS) and 16-doxylstearic acid
(16NS) were obtained from Aldrich (Milwaukee, WI). Cholesterol
(Chol) was from Sigma (St. Louis, MO), and 1,6-diphenylhexatriene
(DPH) as well as trans-parinaric acid (tPnA) were purchased from
Molecular Probes (Eugene, OR). Trp (L-tryptophan), acrylamide,
N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid (HEPES),
NaOH, NaCl, chloroform, ethanol, methanol, and dimethylforma-
mide (spectroscopic grade) were obtained from Merck (Darmstadt,
Germany).
2.2. Sample Preparation. Sifuvirtide and Trp stock solutions
were prepared in 10 mM HEPES buffer, pH 7.4, 150 mM NaCl.
All the experiments were performed at 22 °C, and unless otherwise
stated, all solutions were prepared in the same buffer as the stock
solutions, which is expected to mimic physiological conditions.
Absorption measurements were carried out in a UV-vis spectro-
photometer Jasco V-560, and a Malvern Instruments Zetaziser Nano
ZS equipped with He-Ne laser (632.8 nm, 4.0 mW) was used to
perform the dynamic light scattering (DLS) assays. Fluorescence
assays were performed in a spectrofluorometer SPEX Fluorolog-3
from Horiba Jobin-Yvon, equipped with a 450 W Xe lamp (for
steady-state fluorescence) and a 279 nm wavelength-fixed nano-
second light-emitting diode (for time-resolved fluorescence), Glan-
Thompson autopolarizers FL-1044, double monochromators, a
single-photon detection module TBX-04-A, and a TCSPC acquisi-
tion device DataStation Hub.
2.3. Lipid Preparation. Large unilammelar vesicles (LUV) and
small unilammelar vesicles (SUV) were prepared by extrusion and
sonication methods, as described elsewhere.17,18 LUV were used
as models of biological membranes. Several systems were analyzed,
including POPC, POPC:EPOPC (9:1, 3:1, and 1:1), POPC:Chol
(82:18 and 2:1), DPPC, POPC:DPPC (2:1, 1:1, and 1:2), DPPC:
Chol (2:1), POPC:PSM (2:1) and POPC:PSM:Chol (1:1:1) mixtures.
Atomic force microscopy (AFM) measurements were performed
to visualize phase separation of the mixtures. These experiments
are described in Appendix A (Supporting Information).
2.4. Dynamic Light-Scattering Spectroscopy. For the DLS
studies, 800 µM stock solutions of sifuvirtide were prepared in
filtered HEPES buffer. Successive dilutions of the stock solutions
were performed. The samples were filtered with 0.44 µm pore nylon
membranes before the measurements, and afterward, their concen-
tration was determined by UV-vis absorption measurement at a fixed
wavelength of 280 nm.
DLS was performed by using an incident wavelength of 632.8
nm and a detection angle of 173° (backscatter detection). Measure-
ments were performed at 25 °C, with an incubation time of 15 min.
Data acquisition and analysis was performed by using Malvern DTS
Software (www.malvern.co.uk). The autocorrelation curves were
analyzed by using the CONTIN method.19,20 The average hydro-
dynamic radius was calculated by considering the dominant
population of the intensity distribution of each studied peptide
concentration.
2.5. Steady-State Fluorescence Study. Spectral characterization
of sifuvirtide and Trp in aqueous solution was performed at an
(10) Dwyer, J. J.; Wilson, K. L.; Davison, D. K.; Freel, S. A.; Seedorff,
J. E.; Wring, S. A.; Tvermoes, N. A.; Matthews, T. J.; Greenberg,
M. L.; Delmedico, M. K. Proc. Natl. Acad. Sci. U.S.A. 2007, 104,
12772–12777.
(11) Bystroff, C.; Shao, Y. Bioinformatics 2002, 18, S54–61.
(12) White, S. H.; Wimley, W. C. Biochim. Biophys. Acta 1998, 1376,
339–352.
(13) Lakowicz, J. R. Principles of Fluorescence Spectroscopy, 2nd ed.;
Kluwer Academic/Plenum Publishers: New York, NY, 1999; p 698.
(14) Veiga, S.; Henriques, S.; Santos, N. C.; Castanho, M. Biochem. J.
2004, 377, 107–110.
(15) Veiga, A. S.; Santos, N. C.; Loura, L. M.; Fedorov, A.; Castanho,
M. A. J. Am. Chem. Soc. 2004, 126, 14758–14763.
(16) Bar, S.; Alizon, M. J. Virol. 2004, 78, 811–820.
(17) Mayer, L. D.; Hope, M. J.; Cullis, P. R. Biochim. Biophys. Acta 1986,
858, 161–168.
(18) Szoka, F.; Papahadjopoulos, D. Annu. ReV. Biophys. Bioeng. 1980, 9,
467–508.
(19) Provencher, S. W. Comput. Phys. Commun. 1982, 27, 229–242.
(20) Provencher, S. W. Comput. Phys. Commun. 1982, 27, 213–227.
Figure 1. Amino acid sequence of HIV fusion inhibitors T-1249 (top), enfuvirtide (middle), and sifuvirtide (bottom). The boxes indicate a high sequence
homology between the peptides. Hydrophobic residues are represented in blue, noncharged polar in green, and charged polar in red.
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excitation wavelength of 280 nm, except for the quenching
experiments where the excitation was performed at a wavelength
of 290 nm to minimize the relative quencher/fluorophore light-
absorption ratios. For the red-edge excitation shift experiments,21
the excitation wavelength varied from 280 to 320 nm. Emission
spectra were collected in the 300-450 nm wavelength range, with
an integration time of 0.5 s and an increment of 1 nm. For the
quenching experiments, fluorescence was collected at a fixed
wavelength of 360 nm. Excitation and emission spectra were
corrected for wavelength-dependent instrumental factors.13 During
the quenching and partition experiments, emission was also
corrected for successive dilutions, scatter,22 and simultaneous light
absorptions of quencher and fluorophore.23 The dependence of
fluorescence intensity and quantum yield of sifuvirtide24 on its
concentration was tested over the 0-220 µM range, and for these
assays, fluorescence intensities were corrected for inner filter
effects.25 Whenever a constant concentration of peptide was
required, 15 µM sifuvirtide was used. At this concentration, the
absorbance at 280 nm is below 0.1 (ε ) 1.3 × 104 M-1 cm-1, l )
0.5 cm), ensuring a minimal inner filter effect. Regarding the Trp
solutions, a constant concentration of 36 µM was used during the
experiments. The determination of the relative fluorescence quantum
yield (Φ) of sifuvirtide was performed as indicated in ref 26, by
choosing a Trp solution as standard (Φ ) 0.13). Fluorescence
anisotropy was used to study red-edge effects of sifuvirtide in
aqueous solution (details have been published elsewhere21). All the
data were corrected for background intensities.
2.6. Time-Resolved Fluorescence Study. Fluorescence lifetimes
of sifuvirtide and Trp in aqueous solution were calculated from
time-resolved intensity decays, which were measured at an excita-
tion wavelength of 279 nm and an emission acquisition at a
wavelength of 360 nm by using 20 × 103 counts in the peak
channel. A 50 ns range was used for decay acquisition, and channels
with less than 200 counts were not used for data analysis.
Instrumental response functions were generated from scatter disper-
sion (glycogen solution (Acros Organics, Belgium)). Data analysis
was carried out by using a nonlinear least-squares iterative
convolution method based on the Marquardt algorithm.27 The
goodness of the fit was judged from the global 2 values, distribution
of the residuals, and autocorrelation plot. The fluorescence decay
was complex and described by the sum of two exponentials.13
Sifuvirtide and Trp intensity decays were corrected for back-
ground intensities and scatter. The average lifetime (〈τ〉) and the
fluorescence lifetime averaged by the pre-exponential factors (τj)
were recovered (details have been published elsewhere21).
2.7. Quenching Experiments. Fluorescence quenching assays
of sifuvirtide by acrylamide, 5NS, and 16NS were performed by
both steady-state and time-resolved fluorescence spectroscopy.
Quenching of 15 µM sifuvirtide by acrylamide (0-60 mM) was
studied in buffer and in the presence of 3 mM of lipid (LUV), by
successive additions of small volumes. The quenching assays by
the lipophilic probes 5NS and 16NS were carried out at the same
peptide and lipid concentrations, by successive additions of small
amounts of these quenchers to samples of peptide incubated in LUV,
keeping the ethanol concentration below 2% (v/v).28 The effective
lipophilic quencher concentration in the membrane was calculated
from the partition coefficient of both quenchers to the lipid
bilayers.29 For every addition, a minimal 10 min incubation time
was allowed before measurement.
Quenching data were analyzed by using the Stern-Volmer
equation21 (eq 1) or, when a negative deviation to the Stern-Volmer
relationship was observed, by using eq 2.29,30
I0
I ) 1+KSV[Q] (1)
I0
I )
1+KSV[Q]
(1+KSV[Q])(1- fB)+ (fB)
(2)
where I and I0 are the fluorescence intensity of the sample in the
presence and absence of quencher, respectively, KSV is the
Stern-Volmer constant, [Q] the concentration of quencher, and fB
is the fraction of light accessible to the quencher.
In the case of dynamic quenching, the relationship I0/I ) τj0 /τj is
valid; thus, time-resolved quenching data can be analyzed by using
eqs 1 and 2. Bimolecular rate constants (kq) were calculated ac-
cording to ref 21.
2.8. Extent of Partition to LUV. Membrane partition studies
were performed by successive additions of small amounts of a 15
mM lipid suspension (LUV) to a 15 µM sifuvirtide solution, with
a 10 min incubation time in between each addition. The extent of
the interaction of the peptide with the modeled lipid system was
judged by steady-state and time-resolved fluorescence.
The partition coefficients (Kp) were calculated from the fit of
the experimental data with eq 3.31
I
IW
)
1+KpγL
IL
IW
[L]
1+KpγL[L]
(3)
where IW and IL are the fluorescence intensities in aqueous solution
and in lipid, respectively, γL is the molar volume of the lipid,32,33
and [L] is the lipidic concentration.
In addition to the fluorescence intensities (I), the fluorescence
lifetimes averaged by the pre-exponential factors (τj) could also be
used in eq 3 during the assays.31
The fraction of peptide interacting with membranes (xL) and the
fraction of light emitted by the peptide incorporated in the vesicles
(fL) were determined according to refs 24 and 29.
2.9. Membrane Fluidity Perturbation Assay. To judge the
influence of the peptide sifuvirtide on the fluidity of gel-phase DPPC
membranes, the steady-state anisotropy of tPnA (calculated ac-
cording to ref 21) was studied at a fixed concentration of lipid (3
mM) as a function of the peptide concentration (0-50 µM). A total
of 5 µM of a solution of tPnA in ethanol was added into a 3 mM
lipid suspension of DPPC LUV (1:600 dilution) and was incubated
over 30 min at a temperature above that of the phase transition.34
Ethanol concentration in the sample was kept below 2% (v/v).28
Excitation of tPnA was performed at a wavelength of 318.5 nm,
coinciding with the relative absorption maximum presented by this
probe in DPPC LUV. Emission spectra were collected over the
325-550 nm range, and the fluorescence intensities were corrected
for the dilution effects.
2.10. Förster Resonance Energy Transfer (FRET) Experi-
ment. The evaluation of possible adsorption of sifuvirtide on the
gel-phase DPPC membranes was performed by a FRET study, by
using the Trp residues of the peptide as donors and DPH molecules(21) Santos, N. C.; Castanho, M. Trends Appl. Spectrosc. 2002, 4, 113–
125.
(22) Ladokhin, A. S.; Jayasinghe, S.; White, S. H. Anal. Biochem. 2000,
285, 235–245.
(23) Coutinho, A.; Prieto, M. J. Chem. Educ. 1993, 70, 425–428.
(24) Henriques, S. T.; Castanho, M. A. Biochim. Biophys. Acta 2005, 1669,
75–86.
(25) Kubista, M.; Sjoback, R.; Eriksson, S.; Albinsson, B. Analyst 1994,
119, 417–419.
(26) Fery-Forgues, S.; Lavabre, D. J. Chem. Educ. 1999, 76, 1260–1264.
(27) Marquardt, D. W. SIAM J. Appl. Math. 1963, 11, 431–441.
(28) Yamazaki, M.; Miyazu, M.; Asano, T.; Yuba, A.; Kume, N. Biophys.
J. 1994, 66, 729–733.
(29) Santos, N. C.; Prieto, M.; Castanho, M. A. Biochemistry 1998, 37,
8674–8682.
(30) Lehrer, S. S. Biochemistry 1971, 10, 3254–63.
(31) Santos, N. C.; Prieto, M.; Castanho, M. A. Biochim. Biophys. Acta
2003, 1612, 123–135.
(32) Chiu, S. W.; Jakobsson, E.; Subramaniam, S.; Scott, H. L. Biophys.
J. 1999, 77, 2462–2469.
(33) Nagle, J. F.; Wiener, M. C. Biochim. Biophys. Acta 1988, 942, 1–10.
(34) Castanho, M.; Prieto, M.; Acuna, A. U. Biochim. Biophys. Acta 1996,
1279, 164–168.
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as acceptor.35 Small amounts of DPH in dimethylformamide (DMF)
were added into a DPPC suspension, keeping the DMF concentra-
tion below 1% (v/v). To guarantee a complete incorporation of
DPH, it was incubated for 12 h with DPPC vesicle suspensions at
4 °C. A concentration range of 0-60 µM of DPH in the membranes
(0-2% over the total lipid concentration) was studied. After the
complete incorporation of DPH, peptide was added to the lipid
suspension, and the solution was kept incubating during 10 min at
room temperature. The lipid and peptide final concentrations used
in this assay were 3 mM and 15µM, respectively. Time-resolved
fluorescence was used to evaluate the FRET. Control measurements
of the DPH/DPPC lipid suspensions without peptide were performed
to discard any background intensity and scatter contribution.
Energy-transfer efficiencies, E, were experimentally determined
from eq 4.
E) 1-
τDA
τD
(4)
where τjDA and τjD are the fluorescence lifetimes averaged by the
pre-exponential factors in the presence and absence of acceptor,
respectively.
The theoretical Förster radius (R0, critical distance for energy
transfer) was calculated according to Berberan-Santos and Prieto.36
R0 ) 0.2108[κ2ΦDn-4∫
0
∞
I(λ)ε(λ)λ4dλ]1⁄6 (5)
where κ2 is the orientation factor (the value κ2 ) 2/3, relative to
the dynamic isotropic limit, was used in this study),ΦD is the donor
quantum yield in the absence of acceptor (the value ΦD ) 0.08,
measured in this study for 3 mM DPPC lipid concentration, was
used), n is the refractive index (n ) 1.4 was used in this study as
refractive index within the vesicles37), I(λ) is the normalized donor
emission spectrum, and ε(λ) is the acceptor molar absorption
spectrum (expressed in M-1cm-1). If in eq 5 λ is in nanometers,
the calculated R0 will be in angstroms.
The FRET formalism,15,37 proposed here to evaluate an adsorp-
tion phenomenon, assumes two planes: an acceptor plane at the
center of the DPPC bilayer and a donor plane at a distance W from
the acceptor plane. In this context, the fluorescence decay law of
the donor in the presence of an acceptor (ID,A) is given by
ID,A )AW ID,W(t)+ (1-AW) ID,L(t)F(t) (6)
where AW is the fraction of the molecules in aqueous solution, ID,W
and ID,L are the fluorescence decays of the donor in the buffer and
adsorbed to the lipid vesicles, respectively, and F(t) is the function
that denotes the FRET rate to acceptors at an interplanar plane
distance of W away from the donor. This quantity is given by
F(t)) exp{-2(WR0)2 [DPH][DPPC] aDPPC ×
πR0
2∫
0
1 1- exp[(- t〈τ〉)(R0W)6R6]
R3
dR} (7)
where 〈τ〉 is the average lifetime of the donor, R0 is the Förster
radius, [DPH] is the concentration of DPH, and aDPPC is the area
per DPPC molecule.38 In the absence of acceptor, F(t) ) 0.
The experimental energy-transfer efficiencies were adjusted to
this formalism by calculating the expected energy-transfer efficien-
cies by numerical integration of the theoretical decay laws of the
donor in the presence and absence of acceptor, recovering the values
of W, AW, and R0.
3. Results and Discussion
3.1. Characterization of Sifuvirtide in Aqueous Solution.
Spectra of peptides presenting aromatic residues can give
valuable information about local structural properties.13,21
Fluorescence spectral characteristics of sifuvirtide are dominated
by its two Trp residues (Figure 2A). In solution and under
physiological pH and ionic strength conditions, sifuvirtide (15
µM) has an absorption maximum at 280 nm and an emission
maximum at 347 nm. No red-edge excitation-shift effects were
detected under these conditions. The fluorescence decay of the
peptide was described by the sum of two exponentials with a
mean lifetime of τ ) 2.45 ns (2 e 1.3). A value of Φ ) 0.07
was recovered for the fluorescence quantum yield (Φ) of the
peptide.
Fluorescence quenching of the Trp residues of the peptide
by acrylamide was also studied to verify the accessibility of
the fluorophores. The quenching was evaluated by steady-state
and time-resolved fluorescence to distinguish static from
dynamic quenching behaviors.13,21 A predominance of dynamic
quenching of the fluorescence of sifuvirtide by acrylamide was
observed (Figure 2B). Linear Stern-Volmer plots were obtained
(bimolecular rate constant kq ) (3.26 ( 0.03) × 10-9 M-1 s-1),
revealing that the Trp residues are not localized inside hydro-
phobic pockets and are accessible to the quencher.
All these results suggest that the Trp residues of sifuvirtide
are considerably exposed to the surrounding aqueous medium.13,21
Furthermore, to evaluate possible changes in the supra-
molecular structure of sifuvirtide, the fluorescence quantum yield
dependence and the hydrodynamic radius dependence on peptide
concentration were studied. A concentration-dependent behavior
is often related to different structures of the peptide because of
folding variation or oligomerization.24 Regarding fluorescence
results, no significant deviations from linearity were observed
at concentrations less than 60 µM (Figure 2C). A monomeric
form of the peptide could then be assumed in this situation. At
higher concentrations, a positive deviation from linearity was
observed and could indicate the formation of small aggregates
of peptide, where Trp residues are localized in a less-polar
environment, presenting a higher quantum yield.24 Because light-
scattering techniques have a very low sensitivity for small
aggregates,39 during the dynamic light-scattering assays (Figure
2D), no significant aggregation until a concentration of 600 µM
(near the solubility limit) was revealed.
3.2. Interaction of Sifuvirtide with Biological Membrane
Model Systems.
3.2.1. Extent of Partition into Zwitterionic Lipid Bilayers.
The partition of sifuvirtide into zwitterionic lipid bilayers was
evaluated to study the importance of the lipidic phase in this
interaction. Previous studies revealed that HIV fusion inhibitors
may interact with lipid membranes,14,15 which is regarded as
relevant for their mode of action, because the inhibition process
of this class of peptides occurs in extreme confinement between
the cellular plasmatic membrane and the viral envelope. (See
ref 16 and references therein). Several vesicle systems of varying
lipid composition were analyzed to mimic the different rigidity
(35) Le Doan, T.; Takasugi, M.; Aragon, I.; Boudet, G.; Montenay-
Garestier, T.; Helene, C. Biochim. Biophys. Acta 1983, 735, 259–
270.
(36) Berberan-Santos, M. N.; Prieto, M. J. E. J. Chem. Soc., Faraday Trans.
1987, 83, 1391–1410.
(37) Davenport, L.; Dale, R. E.; Bisby, R. H.; Cundall, R. B. Biochemistry
1985, 24, 4097–4108.
(38) Marsh, D. CRC Handbook of Lipid Bilayers; CRC Press: Boston, 1990. (39) Banachowicz, E. Biochim. Biophys. Acta 2006, 1764, 405–413.
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properties more common at the cellular level. AFM was used
to visualize the existence of the phase separation in several of
those mixtures (Appendix A, Supporting Information). Titrations
of peptide (15 µM) were performed at room temperature with
POPC vesicles (liquid-disordered phase), DPPC or PSM-
containing vesicles (gel phase), and vesicles containing cho-
lesterol in their composition (liquid-ordered phase). No signifi-
cant changes in fluorescence intensity nor spectral blue-shifts
were observed when sifuvirtide was in the presence of POPC,
POPC:Chol (2:1), POPC:PSM:Chol (1:1:1), or DPPC:Chol (2:
1) vesicles. Only in the presence of pure DPPC gel-phase
membranes, a significant increase in the fluorescence intensity
(Figure 3A) and quantum yield, as well as a significant spectral
blue-shift (7 nm), were observed (data not shown). A specific
and preferential interaction of sifuvirtide with the more-rigid
membranes seems to occur, and the increase of fluidity reduces
this interaction (as seen with DPPC:Chol or POPC:DPPC
vesicles). Increased fluorescence lifetimes of sifuvirtide were
also obtained in the presence of gel-phase membranes (data not
shown).
No significant alterations of the fluorescence mean lifetime
of sifuvirtide in the presence of homogeneous liquid-ordered
and liquid-disordered membranes were observed. Nevertheless,
when the peptide was interacting with POPC:DPPC vesicles
(data not shown), the increase in the DPPC content led to an
increase of the mean lifetime of the fluorophore. This suggests
that the interaction of sifuvirtide with biomembranes depends
preferentially on the presence of more rigid membrane regions.
3.2.2. Extent of Partition into Charged Lipid Bilayers. Vesicles
with cationic and anionic phospholipids were used as positive
and negative controls of partition.
The addition of EPOPC, a fluid-phase (at room temperature)
cationic (at pH 7.4) phospholipid, into POPC vesicles forced
the partition of anionic sifuvirtide into the membranes. Large
spectral shifts (data not shown) and an increase in the
fluorescence intensity (Figure 3A), quantum yield (data not
shown), and lifetime (data not shown) were observed. A partition
coefficient of Kp ) (2.2 ( 0.3) × 103 was recovered for the
interaction with POPC:EPOPC (1:1) by using eq 3. Thus, the
use of EPOPC in the vesicles served as positive control for
the interaction with fluid-phase membranes, discarding the
hypothesis that interaction with POPC could occur without being
reported by Trp fluorescence because of any kind of shielding.
DPPG vesicles were used as negative control for the interac-
tion of sifuvirtide with DPPC gel-phase membranes. The
repulsion between the negatively charged glycerol headgroup
and sifuvirtide prevents the peptide from interacting with gel-
phase vesicles. Thus, at variance with the interaction between
sifuvirtide and DPPC vesicles, no interaction was observed with
DPPG vesicles (Figure 3A).
3.2.3. Quenching of Sifuvirtide with Acrylamide in the Pre-
sence of Lipid Vesicles. Acrylamide is a soluble quencher in
aqueous solution with low capacity for penetration into lipid
bilayers.40 It is generally utilized to verify the aqueous environ-
ment accessibility of the Trp residues in the peptide structure24,41,42
and infer on the depth of interaction between peptides and lipid
Figure 2. Characterization of sifuvirtide in aqueous solution. (A) Absorption (dotted line) and fluorescence emission (solid line) spectra of 15 µM sifuvirtide.
Emission was induced by exciting sifuvirtide at a wavelength of 280 nm. (B) Quenching of the Trp residues of 15 µM sifuvirtide (circles) and 36 µM free
Trp in solution (triangles) by the soluble quencher acrylamide by using steady-state (solid symbols) and time-resolved (open symbols) fluorescence. Dashed
and solid lines are fittings of eq 1 to the experimental data. (C) Fluorescence intensity dependence on sifuvirtide concentration. A positive deviation of
linearity was detected. (D) Hydrodynamic radius dependence on sifuvirtide concentration, studied by dynamic light-scattering spectroscopy. Each point
corresponds to an average of 5-13 measurements. Error bars represent the standard deviation. All the assays were performed in a 10 mM HEPES buffer,
pH 7.4, containing 150 mM NaCl.
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bilayers.24,41 By interacting with membranes, the peptide is less
accessible to the quencher in solution, and therefore, the
fluorescence intensity and lifetime will be less quenched. A
characteristic negative deviation in the Stern-Volmer relation-
ship (eq 1) can then be observed, and by fitting the Lehrer
equation (eq 2) to the data, it is possible to obtain the fraction
of peptide that is buried in the lipid bilayers. Therefore, the use
of acrylamide in this context complements the partition assays
previously described.
Quenching Stern-Volmer plots in the presence of 3 mM of
lipid and 15 µM of peptide revealed a linear profile, similar to
the quenching profile observed for sifuvirtide in solution, for
almost all the vesicle systems analyzed. The exceptions were
DPPC vesicles and POPC:EPOPC vesicles (Figure 3B). In these
cases, negative deviations to the Stern-Volmer relationship
were observed, indicating the presence of a fraction of peptide
that is interacting with the vesicles and is consequently less
accessible to the quencher. By fitting the Lehrer equation (eq
2) to the data, the values of the emission intensity fraction
accessible to the quencher, fB ) 0.84 and fB ) 0.29, were
recovered in the presence of DPPC and POPC:EPOPC (1:1)
vesicles, respectively. Considering that acrylamide has a low
affinity to the lipid, the values of the fraction of fluorescence
intensity originating from the peptide in the lipid (fL) can then
be obtained, fL ) 1- fB (Table 1).
3.2.4. Localization of Sifuvirtide in Lipid Bilayers. A dif-
ferential quenching approach by combining two lipophilic Trp
quenchers enables one to determine the distribution of the
location of the Trp residues of sifuvirtide in the lipid bilayers.43
The probes 5NS and 16NS were used as quenchers. The
efficiency of quenching depends on the proximity of the Trp
residues of the peptide to the quenchers. Considering their
distributions, 5NS probes essentially the interface of the bilayers,
whereas 16NS probes its core.
As expected, no changes in the fluorescence intensity and
lifetime were detected in the presence of 5NS and 16NS in
POPC or POPC:Chol vesicles. This result is further evidence
of nonsignificant interaction of the peptide with fluid-phase and
cholesterol-enriched membranes (liquid-ordered phase). Nev-
ertheless, in the presence of DPPC and POPC:EPOPC (3:1 and
1:1) LUVs, the fluorescence of the Trp residues of sifuvirtide
was quenched by 5NS and 16NS. A negative deviation to the
Stern-Volmer relationship was recovered (Figure 4A), indicat-
ing the presence of two subpopulations of fluorophore relatively
to the accessibility to the quenchers. The Stern-Volmer
constants (KSV) and the fraction of peptide accessible to the
quenchers (fB) were recovered by using eqs 1 and 2 and are
presented in Table 1.
Steady-state fluorescence revealed that the peptide was more
efficiently quenched by 5NS, indicating a preferred location near
the lipid bilayer interface. Time-resolved fluorescence was
utilized to evaluate the predominance of static or dynamic
quenching effects13 by 5NS and 16NS. Dynamic quenching was
predominant; but for 5NS, a strong static contribution was
detected, especially in the POPC:EPOPC vesicles. This elevated
static contribution is due to the close proximity of the fluoro-
phore to the 5NS quencher. It is also interesting that the
quenching efficiency is increased (higher KSV) in gel-phase
membranes. This can be caused by a segregation effect of both
quencher and peptide to defect lines on the gel membrane,
enabling a local concentration that favors efficiency enhancement.
The fB values obtained by applying the Lehrer equation (eq
2) to the 5NS and 16NS quenching experimental data can be(40) Moro, F.; Goni, F. M.; Urbaneja, M. A. FEBS Lett. 1993, 330, 129–
132.
(41) Melo, M. N.; Castanho, M. A. Biochim. Biophys. Acta 2007, 1768,
1277–1290.
(42) Veiga, A. S.; Castanho, M. A. FEBS J. 2007, 274, 5096–50104.
(43) Fernandes, M. X.; Garcia de la Torre, J.; Castanho, M. A. Anal.
Biochem. 2002, 307, 1–12.
Figure 3. Interaction of sifuvirtide with lipid membranes. (A) Partition of
15 µM sifuvirtide into large unilamellar vesicles performed by successive
additions of a concentrated LUV suspension. (B) Fluorescence quenching
of 15 µM sifuvirtide by acrylamide in the presence of 3 mM lipid vesicles.
All the assays were performed in a 10 mM HEPES buffer, pH 7.4, containing
150 mM NaCl. The line is a fitting of eq 3 to the experimental data. Studied
systems: aqueous solution (solid triangles); POPC (hexagons); DPPC
(squares); POPC:Chol (diamonds); DPPG (open triangles); POPC:EPOPC
(3:1, open circles); and POPC:EPOPC (1:1, solid circles).
Table 1. Parameters Obtained for the Quenching of the
Fluorescence of Sifuvirtide by Acrylamide and by the Lipophilic
Probes 5NS and 16 NSa
POPC:EPOPC (1:1) DPPC
steady state time resolved steady state time resolved
KSV,acryl (M-1) 12.5 ( 3.10 8.80 ( 2.00
fB,acryl 0.29 ( 0.16 0.84 ( 1.06
fL,acryl 0.71 ( 0.40 0.16 ( 0.21
KSV,5NS (M-1) 6.70 ( 0.80 1.90 ( 0.06 6.94 ( 2.70 12.6 ( 6.30
KSV,16NS (M-1) 2.20 ( 0.40 2.40 ( 0.07 21.3 ( 10.2 12.5 ( 2.30
fB,5NS 0.79 ( 0.32 1 0.29 ( 0.24 0.14 ( 0.15
fB,16NS 0.86 ( 0.73 1 0.12 ( 0.12 0.15 ( 0.06
a Assays were performed in a 10 mM HEPES buffer, pH 7.4,
containing 150 mM NaCl. Quenching experiments were performed at a
total lipidic concentration of 3 mM. KSV and fB were determined by
fitting eq 2 or eq 1 (fB ) 1) to the experimental data. fL,acryl was
obtained by fL ) 1 - fB.
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compared to the fL values obtained for the partition of sifuvirtide
into the different vesicle systems24 and to fL values obtained
for the fluorescence quenching with acrylamide. As seen in
Table 1, given the intrinsic experimental error, fB,5NS and fB,16NS
are in agreement with fL,acryl for the interaction of sifuvirtide
with DPPC and POPC:EPOPC vesicles.
An improved version of the SIMEXDA method43 that takes
into account the possibility of static quenching by using a
sphere-of-action methodology44 was used to obtain the in-depth
distribution of the Trp residues of sifuvirtide in DPPC and
POPC:EPOPC (1:1) vesicles. Regarding the interaction with gel-
phase DPPC vesicles (Figure 4B), a superficial location of the
Trp residues of sifuvirtide was observed. As the maximum of
the distribution coincides with the top of the bilayer, an
adsorption of sifuvirtide on these rigid membranes is suggested,
but insertion to a certain extent cannot be yet discarded. In
contrast, for the electrostatic interaction of the peptide with
POPC:EPOPC (1:1), the distribution of the Trp residues suggests
an insertion in the bilayer (Figure 4B).
3.2.5. Adsorption of Sifuvirtide on Gel Phase Membranes.
The preference of sifuvirtide for gel-phase membranes is quite
meaningful and was further studied. The quenching and partition
studies suggest a superficial location of sifuvirtide and a low
extent of partitioning to the gel-phase membranes. An adsorption
interaction can be hypothesized.
tPnA is a fluorescent tetraene fatty acid with partitions
preferentially into gel-phase membranes,34,45 commonly used
as a probe in phase-transition studies.46 If the peptide inserts
into membranes, a pertubation in the anisotropy value of tPnA
should be detected because of the fluidification of the membrane
caused by this insertion. As the peptide sifuvirtide was added
to a suspension of DPPC vesicles (3 mM) with 1:600 M of
tPnA, no changes in the average anisotropy of tPnA were
detected (data not shown), showing that the interaction of the
peptide does not lead to a significant perturbation of the
membrane fluidity. These results are consistent with a superficial
interaction of the peptide with gel-phase membranes and in
agreement with the adsorption hypothesis.
To confirm the adsorption, a FRET experiment was conducted
by using the Trp residues of sifuvirtide as donor and DPH as
acceptor. DPH is a rigid rodlike fluorescent probe that is a
suitable acceptor to Trp35 because of the overlapping of its
absorption spectrum with the emission spectrum of Trp. This
probe partitions deeply within the core of the bilayer. Molecular
dynamics studies reveal that DPH prefers to be accommodated
in the hydrophobic acyl chain region of DPPC, oriented with
its long axis parallel to the bilayer normal.47 For the sake of
simplicity, a commonly used distribution of DPH at the center
of the bilayer can be considered as a reasonable crude ap-
proximation,37 also given that the DPH molecules will distribute
symmetrically between the two bilayer leaflets.
Energy transfer was followed by time-resolved fluorescence
in the presence of 3 mM of DPPC, 15 µM of sifuvirtide, and
a variable concentration of DPH (0-2%). An increase in the
energy-transfer efficiency with the DPH content was observed
(Figure 5A). The existence of FRET is a direct evidence of
an interaction of sifuvirtide with DPPC gel-phase membranes.
By calculating the energy-transfer efficiencies through nu-
merical integration of the theoretical decay laws (eqs 6 and
7), not only the interplanar distance (W) can be recovered
but also the Förster radius (R0) and the fraction of peptide in
solution (AW) (and consequently the adsorption coefficient
(Ka)). A Förster radius of 29.9 Å was obtained by using this
methodology, which is in agreement with the Förster radius
obtained (30.6 Å) for the Trp-DPH donor-acceptor pair36
(eq 5). We have estimated an interplanar distance of 32.4 Å
between DPH (at the center of the bilayer) and the Trp
residues of sifuvirtide. Sifuvirtide adopting an R-helical
secondary structure is expected to have a maximum diameter
of 15 Å (calculated by using PyMOL, http://www.pymol.org).
Assuming a 44 Å length for a gel-phase DPPC bilayer,38 22
Å < W < 37Å is estimated, depending on the orientation of
the Trp residues. The interplanar distance experimentally
obtained (W ) 32.4 Å) lies in this range and, therefore, is in
agreement with the adsorption (Figure 5B). A hypothetical
value of AW ) 0.75 was obtained; thus, Ka ) 0.16 × 103 is
retrieved, indicating a reasonable degree of adsorption of
sifuvirtide on the surface of the gel-phase membranes.
(44) Castanho, M. A.; Prieto, M. J. Biochim. Biophys. Acta 1998, 1373,
1–16.
(45) Sklar, L. A. Mol. Cell. Biochem. 1980, 32, 169–77.
(46) de Almeida, R. F.; Loura, L. M.; Fedorov, A.; Prieto, M. Biophys. J.
2002, 82, 823–834.
(47) Repakova, J.; Capkova, P.; Holopainen, J. M.; Vattulainen, I. J. Phys.
Chem. B 2004, 108, 13438–13448.
Figure 4. Location of 15 µM sifuvirtide in lipid bilayers (3 mM). (A)
Stern-Volmer plot of the quenching of 15 µM sifuvirtide by 5NS (solid
symbols) and 16NS (open symbols) in POPC:EPOPC (1:1) (triangles) and
DPPC (circles) by using steady-state fluorescence spectroscopy. Dashed
and solid lines are fittings of eq 2 to the experimental data. (B) In-depth
distribution of the Trp residues of sifuvirtide in lipid bilayers by using the
SIMEXDA method. The location is mainly interfacial for POPC:EPOPC
(1:1) vesicles (dashed line) and superficial for DPPC vesicles (solid line).
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4. Conclusions
Sifuvirtide is a second generation HIV fusion inhibitor, which
revealed promising results during the preclinical evaluation and
clinical trials.8,9
In solution, sifuvirtide has a monomeric (or a small oligo-
meric) form, and no extensive oligomerization occurs until
saturation. Therefore, this peptide can present clinical advantages
in its administration, as well as in its molecular action to inhibit
the virus entry.
The use of fluorescence spectroscopy-based methodologies
revealed an unique selectivity of sifuvirtide to gel-phase
membranes. At variance with other peptidic fusion inhibitors,
such as enfuvirtide or T-1249, sifuvirtide does not partition into
more fluid noncharged membranes. Enfuvirtide presents a high
affinity for POPC fluid membranes,14 and T-1249, complemen-
tarily to its affinity to POPC fluid membranes, adsorbs at the
surface of cholesterol-rich domains.15 Sifuvirtide is remarkably
efficient in screening and adsorbing only to the rigid lipid
platforms, as seen in the quenching and FRET experiments. On
the other hand, it does not have a significant interaction neither
with POPC fluid membranes nor cholesterol-rich membranes.
This is compatible with its lower hydrophobicity, compared to
both enfuvirtide and T-1249.
Although partitioning of enfuvirtide and T-1249 to mem-
branes contributes to the high efficacy to inhibit the HIV entry
into the cells,48 this phenomenon is not as selective as for
sifuvirtide, considering the fact that the receptors essential to
the fusion mechanism are localized in very rigid domains of
the membrane. Lipid rafts (cholesterol and sphingomyelin-rich
domains) are considered as essential for the virus entry.49 The
rigidity of the domains is an important factor for the inhibition
or the enhancement of the virus fusion capacity. Fluidification
of the membrane by depletion of cholesterol and subsequent
destruction of the rafts inhibit the HIV entry because of the
loss of the signaling pathways and receptor functions.50 On the
other hand, turning the membrane more rigid, as shown in
ceramide-rich membranes (ceramide platforms), also inhibits
the virus entry because of restrictions on the lateral diffusion
of the receptors needed for the membrane fusion.51 It is known
that the receptors on the cell used for the viral fusion (e.g., CD4)
are associated to more-rigid neutral glycosphingolipid (GSL)-
rich microdomains.52,53 The existence of gel-phase micro-
domains inside rafts is quite controversial, in part because of
the difficulties associated to their determination. Nevertheless,
studies of sphingomyelin/cholesterol/ganglioside (or ceramide)
ternary mixtures revealed the existence of gel-phase domains,
rich in sphingomyelin and ganglioside (or ceramide), distinct
and separated from the liquid-ordered sphingomyelin and
cholesterol-rich domains.54–56 The presence of GSL-binding
domains on the V3 domain of HIV envelope protein gp120 is
an evidence of the importance of GSL microdomains for the
infection of HIV into the immune cells.52,53 The affinity of the
fusion inhibitor peptide T-1249 to the liquid-ordered rafts
explains its improved efficacy relative to enfuvirtide. The
selectivity and targeting of sifuvirtide toward more-rigid gel-
phase domains, as seen in our results, is probably a key factor
to explain the 20-fold increase of efficacy relative to enfuvirtide.
Other factors include a higher half-life and a larger affinity to
gp41, and a possible specific interaction with the viral membrane
because of its high enrichment on DPPC (and other saturated
phosphotidylcholines) relative to the host membrane.57
This study shows that there is a trend between fusion inhibitor
efficacy and the ability of drug peptides to adsorb to rigid lipid
domains. According to our results, we can hypothesize a
molecular mode of action for sifuvirtide on the HIV target-cell
membranes and/or on the viral membrane. Sifuvirtide’s ability
to screen the more-rigid domains of the membranes provides a
(48) Castanho, M. A.; Fernandes, M. X. Eur. Biophys. J. 2006, 35, 92–
103.
(49) Campbell, S. M.; Crowe, S. M.; Mak, J. J. Clin. Virol. 2001, 22, 217–
227.
(50) Nguyen, D. H.; Taub, D. D. Mol. InterV. 2004, 4, 318–320.
(51) Finnegan, C. M.; Rawat, S. S.; Cho, E. H.; Guiffre, D. L.; Lockett,
S.; Merrill, A. H., Jr.; Blumenthal, R J. Virol. 2007, 81, 5294–5304.
(52) Hammache, D.; Yahi, N.; Maresca, M.; Pieroni, G.; Fantini, J. J. Virol.
1999, 73, 5244–5248.
(53) Puri, A.; Hug, P.; Jernigan, K.; Barchi, J.; Kim, H. Y.; Hamilton, J.;
Wiels, J.; Murray, G. J.; Brady, R. O.; Blumenthal, R. Proc. Natl.
Acad. Sci. U.S.A. 1998, 95, 14435–14440.
(54) Ferraretto, A.; Pitto, M.; Palestini, P.; Masserini, M. Biochemistry 1997,
36, 9232–9236.
(55) Silva, L. C.; de Almeida, R. F.; Castro, B. M.; Fedorov, A.; Prieto,
M. Biophys. J. 2007, 92, 502–516.
(56) Castro, B. M.; de Almeida, R. F.; Silva, L. C.; Fedorov, A.; Prieto,
M. Biophys. J. 2007, 93, 1639–1650.
(57) Brügger, B.; Glass, B.; Haberkant, P.; Leibrecht, I.; Wieland, F. T.;
Kräusslich, H. G. Proc. Natl. Acas. Sci. U.S.A. 2006, 103, 2641–2646.
Figure 5. Energy transfer from Trp residues of sifuvirtide (donor) to DPH (acceptor) in DPPC vesicles (3 mM). (A) FRET efficiencies obtained at different
proportions of DPH. (B) The schematic representation of the FRET assay suggests an adsorption of sifuvirtide on DPPC gel bilayers. FRET results suggest
that the peptide is adsorbed at the surface of DPPC rigid membranes. R0 ≈ 30 Å; W ) 32.4 Å; xL (fraction in lipid) ≈ 0.25. Peptide molecules located in
the bulk aqueous phase (depicted at the top of the figure) are not quenched by FRET.
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local increased concentration of the drug at the fusion site.
Consequently, this study may help explain the improved clinical
efficacy of this peptide compared to that of other drugs from
the same class.
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